To include your compound in the COVID-19 Resource Center, submit it here.

RedHill's Bekinda meets in Phase III gastroenteritis trial

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) reported top-line data from the Phase III GUARD trial in 321 patients ages >12 with acute gastroenteritis and gastritis showing

Read the full 269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE